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Background
Erlotinib and Gefitinib have proven efficacy in patients
with non small cell lung cancer (NSCLC). However,
evidence for a direct comparison between the two treat-
ments does not exist. We conducted a mixed treatments
comparison (MTC), so that an indirect comparison of
Erlotinib vs. Gefitinib can be made and a formal
economic evaluation can be consequently undertaken.
Methods
Evidence was synthesized from published randomised
controlled phase III trials , including recent evidence for
Erlotinib from a trial sponsored by the CRUK & UCL
Cancer Trials Centre comparing Erlotinib with Placebo.
The effects of Erlotinib and Gefitinib on overall survival
(OS) and progression-free survival (PFS) were compared
using a MTC method with Placebo as the common
comparator. A Bayesian approach was used to carry out
the MTC. A further economic evaluation was underta-
ken under a Bayesian framework.
Results
Seven randomised controlled trials were included. Both
interventions offered improvements in OS and PFS
compared with placebo. Using MTC analysis, the OS
hazard ratio (HR) for Erlotinib vs. Placebo was 0.83;
95% credible interval (CI) of (0.31 , 2.38); for PFS
HR=0.81; 95% CI (0.12,5.65); for Gefitinib vs Placebo:
OS HR= 0.86; 95% CI (0.27, 2.54); PFS HR was 0.42;
95% CI (0.06,2.79); OS HR for Erlotinib vs Gefitinib was
0.98; 95% CI (0.24,4.58) and for PFS was 1.84; 95% CI
(0.14, 31.2).
Conclusion
Both Erlotinib and Geftinib show improved OS and PFS
over Placebo on average. However, although Erlotinib and
Gefitinib appear equivalent in terms of OS, Gefitinib
appears to offer improved PFS. This is likely to improve
HRQoL prior to progression and have an important
impact on the cost per Quality Adjusted Life Year
(QALY).
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